News

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...
Biomednewsbreaks - Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Safety Results In Phase 2 Study Of Prostate Cancer Drug ENV-105
Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company developing cancer therapies, announced favorable interim safety results from ...
Why Is Kairos Pharma Stock Surging On Tuesday?
Kairos Pharma reported strong safety results from a Phase 2 trial of ENV-105 in mCRPC, with no serious toxicities seen in the ...
Kairos Pharma Shares Surge on Prostate Cancer Study Results
Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.
Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
Wells Fargo posted adjusted earnings of $1.54 per share, beating market estimates of $1.40 per share. Wells Fargo reported a net interest income of $11.71 billion on Tuesday, down ...
InvestorsHub on MSN23h
Kairos Pharma Shares Surge on Promising Safety Data for Prostate Cancer Treatment
Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic ...
Fierce Pharma1d
As Perrigo's streamlining takes shape, self-care specialist offloads OTC dermatology unit for up to €327M
Under the transaction, Perrigo is handing over several popular skincare franchises, including ACO, Biodermal, Emolium and Iwostin. Perrigo acquired the latter two Eastern European brands, plus the non ...
Kairos Pharma stock soars after positive safety data for cancer drug
Investing.com -- Kairos Pharma Ltd (NYSE: KAPA) stock surged 165% after the clinical-stage biopharmaceutical company reported positive safety results from its ongoing Phase 2 clinical trial of ENV-105 ...
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...
Investing1mon
Kairos Pharma presents promising cancer drug data
LOS ANGELES - Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company with a market capitalization of $9.91 million, has presented new data on its investigational cancer ...
Eagle-Tribune1mon
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand ...
LOS ANGELES-- (BUSINESS WIRE)--Jun 3, 2025--Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of ...